Intestinal permeability in a patient with liver cirrhosis

Therapeutics and Clinical Risk Management

Volumn 12, Issue , 2016, Pages 1729-1748

  Aguirre Valadez, Jonathan Manuel ^a   Rivera Espinosa, Liliana ^b   Méndez Guerrero, Osvely ^a   Chávez Pacheco, Juan Luis ^b   García Juárez, Ignacio ^a   Torre, Aldo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

Bacterial translocation; Hepatic encephalopathy; Intestinal permeability; Liver cirrhosis; Spontaneous bacterial peritonitis; Variceal hemorrhage

Indexed keywords

ANTIBIOTIC AGENT; B CELL ACTIVATING FACTOR; CHEMOKINE RECEPTOR CX3CR1; CISAPRIDE; CLAUDIN; GAMMA INTERFERON; GAP JUNCTION PROTEIN; INTERLEUKIN 10; INTERLEUKIN 25; INTERLEUKIN 4; INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE; MUCIN 2; MUCIN 3; NITRIC OXIDE; NORFLOXACIN; OBETICHOLIC ACID; OCCLUDIN; PROBIOTIC AGENT; PROPRANOLOL; RIFAXIMIN; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRICELLULIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNINDEXED DRUG; ZONULA OCCLUDENS PROTEIN;

APOPTOSIS; BACTEREMIA; BACTERIAL OVERGROWTH; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; CELL JUNCTION; CYTOSKELETON; DISEASE SEVERITY; DYSBIOSIS; ENTEROENDOCRINE CELL; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; GENE EXPRESSION; GOBLET CELL; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; INTESTINE WALL; LIVER CIRRHOSIS; LIVER INJURY; MACROPHAGE; NONHUMAN; PANETH CELL; PERMEABILITY BARRIER; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINE; STOMACH VARICES BLEEDING; T LYMPHOCYTE; VARICEAL HEMORRHAGE;

EID: 84996956211     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S115902     Document Type: Review

References (147)

1. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;13: 1279-1290.
2. Munoz SJ. Hepatic encephalopathy. Med Clin North Am. 2008;92(4): 795-812.
3. Olson J, Wendon JA, Kramer DJ, et al. Intensive care of the patient with cirrhosis. Hepatology. 2011;54(5):1864-1872.
4. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012; 590(3):447-458.
5. Pleguezuelo M, Benitez JM, Jurado J. Diagnosis and management of bacterial infections in decompensated cirrhosis. World J Hepatol. 2013; 27:6-25.
6. Thalheimer U, De Lorio F, Capra F, et al. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol. 2010;22(10):1228-1234.
7. Cirera I, Beuer TM, Navasa M. Bacterial translocation of enteric organism in patients with cirrhosis. J Hepatol. 2001;34:32-37.
8. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27(5):1207-1212.
9. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double blind, placebo-controlled trial. Hepatology. 1990;12:716-724.
10. Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology. 2009;492087:107.
11. Pardo A, Bartoli R, Lorenzo Zúñiga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology. 2000;31:858-863.
12. Pérez Páramo M, Muñoz J, Albillos A, et al. Effect of propranolol on factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31:43-48.
13. Such J, Guardiola JV, de Juan J, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2002;14(4):371-376.
14. Nischalke HD, Berger C, Aldenhoff K, et al. Toll like receptor (TLR2) promoter and intron 2 polymorphism are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol. 2011;55:1010-1016.
15. Reiberger T, Ferlitsch A, Payer BA, et al. Non selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL6 in patients with cirrhosis. J Hepatol. 2013;58:911-921.
16. Turner J. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799-809.
17. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28(5):1187-1190.
18. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103(1):264-274.
19. Qin X, Caputo FJ, Xu DZ, Deitch EA. Hydrophobicity of mucosal surface and its relationship to gut barrier function. Shock. 2008;29(3): 372-376.
20. Swidsinski A, Sydora BC, Doerffel Y, et al. Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis. 2007;13(8):963-970.
21. Salvo-Romero E, Alonso Cotoner C, Pardo-Camacho C, et al. The intestinal barrier function and its involvement in digestive disease. Rev Esp Enferm Dig. 2015;107:686-696.
22. Pott J, Hornef M. Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep. 2012;13(8):684-698.
23. Zeuthen L, Fink L, Frokiaer H. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-beta. Immunology. 2008;123(2):197-208.
24. Zaph C, Du Y, Saenz S, et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med. 2008;205(10):2191-2198.
25. Xu W, He B, Chiu A, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8(3):294-303.
26. He B, Xu W, Santini P, et al. Intestinal bacteria trigger T cellindependent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26(6): 812-826.
27. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2015;0:1-10.
28. Odenwald M, Turner G. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013;11(9):1075-1083.
29. Caricilli AM, Castoldi A, Câmara NO, et al. Intestinal barrier: a gentlemen’s agreement between microbiota and immunity. World J Gastrointest Pathophysiol. 2014;5(1):18-32.
30. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. 2013;70(4):631-659.
31. Baum B, Georgiou M. Dynamic of adherens junction in epitelial establishment, maintenance, and remodeling. J Cell Biol. 2011;192:907-917.
32. Balda M, Matter K. Tight junctions at a glance. J Cell Sci. 2008;121: 3677-3682.
33. Schulzke J, Fromm M. Tight junctions: molecular structure meets function. Ann N Y Acad Sci. 2009;1165:1-6.
34. Rao R. Occludin phosphorylation in regulation of epithelial tight junctions. Ann N Y Acad Sci. 2009;1165:62-68.
35. Hartsock A, Nelson W. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008;1778(3):660-669.
36. Liu Y, Nusrat A, Schnell F, et al. Human junction adhesion molecule regulates tight junction resealing in epithelia. J Cell Sci. 2000;113(pt 13): 2363-2374.
37. Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol. 2005;171(6):939-945.
38. Ye D, Guo S, Al-Sadi R, Ma TY. Micro RNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011;141(4): 1323-1333.
39. Balmer ML, Slack E, de Gottardi A, et al. The liver may act as a firewall mediating mutusalism between the host and its gut comensal microbiota. Sci Transl Med. 2014;6:237-266.
40. Schneider KM, Beighs V, Heymann F, et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology. 2015;62(5):1405-1416.
41. Frazier TH, DiBaise JK, McClain CJ. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr. 2011;35(5 suppl):14S-20S.
42. Genescà J, Martí R, Rojo F, et al. Increased tumor necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut. 2003;52:1054-1059.
43. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. 2012;42(4):439-446.
44. Anad RJ, Dai S, Rippel C, et al. Activated macrophages inhibit enterocyte gap junctions via the release of nitric oxide. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G109-G119.
45. Plessis JD, Vanheel H, Janseen CEI, et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol. 2013;58(6):1125-1132.
46. Medina-Contreras O, Greem D, Laur O, et al. CX3CR1 regulates intestinal macrophages homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest. 2011;121:4787-4795.
47. Xie YR, Liu SL, Liu X, et al. Intestinal microbiota and innate immunity-realted gene alteration in cirrhotic rats with liver transplantation. Transplant Proc. 2011;43:3973-3979.
48. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(12): 691-701.
49. Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal overgrowth: an evidence-based approach. Curr Gastroenterol Rep. 2016;18:8.
50. Roland BC, Garcia-Tsao G, Ciarleglio MM, et al. Decompensated cirrhotics have slower intestinal transit time as compared with compensated cirrhotics and healthy controls. J Clin Gastroenterol. 2013; 47:888-893.
51. Chang CS, Chen GH, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis. Scand J Gastroenterol. 2001; 36:92-96.
52. Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303(6):G675-G685.
53. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940-947.
54. Bajaj JS, Betrapally ND, Hylemon PH, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62(4):1260-1271.
55. Henao Mejía J, Elinav E, Jin C, et al. Inflammasome mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482: 179-185.
56. Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Physiol. 2012;302(1):G168-G175.
57. Cariello R, Federico A, Sapone A, et al. Intestinal permeability in patients with chronic liver diseases: its relationship with a etiology and the entity of liver damage. Dig Liv Dis. 2010;42:200-204.
58. Scarpellini E, Valenza V, Gabrielli M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol. 2010;105(2):323-327.
59. Pijls KE, Koek GH, Elamin EE, de Vries H, Masclee AA, Jonkers DM. Large intestine permeability is increased in patients with compensated liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014; 306(2):G147-G153.
60. Kalaitzakis E, Johansson JE, Bjarnason I, Björnsson E. Intestinal permeability in cirrhotic patients with and without ascites. Scand J Gastroenterol. 2006;41(3):326-330.
61. Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology. 2003;38(6):1508-1515.
62. Bellot P, Garcia-Pagan JC, Frances R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction inpatients with cirrhosis. Hepatology. 2010;52(6):2044-2052.
63. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37(1):208-217.
64. Hartmann P, Haimerl M, Mazagova M, et al. Toll like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012;143:1330-1340.
65. Douhara A, Moriya K, Yoshiji H, et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep. 2015;11(3):1693-1700.
66. Moreau R, Jalan R, Gines P, et al. Acute on chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426-1437.
67. Gusto T, Felleiter P, Pickkers P, et al; EPIC II Group of Investigators. Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study. Liver Int. 2014; 34(10):1496-1503.
68. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology. 1995;108(6):1828-1834.
69. Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-752.
70. Chavez T, Barrientos-Gutierrez T, Tellez AF, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding an update Cochrane review. Aliment Pharmacol Ther. 2011; 34:509-518.
71. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis. 1997;17(3):203-217.
72. Appenrodt B, Grünhage F, Gentemann MG, et al. Nucleotide binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacetrial peritonitis in liver cirrhosis. Hepatology. 2010;51:1327-1333.
73. Bruns T, Peter J, Reuken PA, et al. NOD 2 gene variants are a risk factor for culture positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int. 2012;32:223-230.
74. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18:353-358.
75. Shah N, Dhar D, El Zahraa MF, et al. Prevention of acute kidney injury in a rodent model of cirrhosis follow in selective gut decontamination is associated with reduce renal TLR4 expression. J Hepatol. 2012; 56:1047-1053.
76. Angeli P, Brun P, Cesari M, et al. Prevalence of bacterial DNA in patients with cirrhosis and refractory ascites and its role in the development of cardiac and renal dysfunctions. Hepatology. 2010;52:342A.
77. Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function inpatients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol. 2012;10:815-818.
78. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818-824.
79. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20:1495-1501.
80. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology. 2002;35: 622-629.
81. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993;18:1139-1143.
82. Blei AT. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol. 2004;40:327-330.
83. Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not amonia, are associated with grade 3/4 hepatic encephalopathy, but nor mortality in cirrhosis. J Hepatol. 2011;54: 640-649.
84. Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and periphereal bacterial DNA in cirrhotic patients. Dig Dis Sci. 2010;55:1465-1471.
85. Vogt A, Reuken PA, Stengel S, Stallmach A, Bruns T. Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: a prospective study. World J Gastroenterol. 2016;22(11):3275-3284.
86. Liboredo JC, Vilela EG, Ferrari Mde L, et al. Nutrition status and intestinal permeability in patients eligible for liver transplantation. JPEN J Parenter Enteral Nut. 2015;39:163-170.
87. Flass T, Tong S, Frank DN, et al. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One. 2015;10(2): e0116967.
88. Giorgio V, Miele L, Principessa L, et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46:556-560.
89. Norman K, Pirlich M, Schulzke JD, et al. Increased intestinal permeability in malnourished patients with liver cirrhosis. Eur J Clin Nutr. 2012; 66(10):1116-1119.
90. Kim BI, Kim HJ, Park JH, et al. Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage. J Gastroenterol Hepatol. 2011;26(3): 550-557.
91. Feld JJ, Meddings J, Heathcote EJ. Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci. 2006;51(9):1607-1613.
92. Zuckerman MJ, Menzies IS, Ho H, et al. Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes. Dig Dis Sci. 2004;49(4):621-626.
93. Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology. 2003;50(53): 1482-1486.
94. Xu WH, Wu XJ, Li JS. Influence of portal pressure change on intestinal permeability in patients with portal hypertension. Hepatobiliary Pancreat Dis Int. 2002;1(4):510-514.
95. Fujii T, Seki T, Maruoka M, et al. Lactulose-L-rhamnose intestinal permeability test in patients with liver cirrhosis. Hepatol Res. 2001;19: 158-169.
96. Parlesak A, Schäfer C, Schütz T, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32(5):742-747.
97. Sun Z, Wang X, Andersson R. Role of intestinal permeability in monitoring mucosal barrier function. History, methodology, and significance of pathophysiology. Dig Surg. 1998;15(5):386-397.
98. Lee S, Son SC, Han MJ, et al. Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites. World J Gastroenterol. 2008;14(24): 3884-3890.
99. Menzies IS. Absorption of intact oligosaccharide in health and disease. Biochem Soc Trans. 1974;1:1042-1046.
100. Van Elburg RM, Uil JJ, Mulder CJ, Heymans HS. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut. 1993;34(3):354-357.
101. Dastych M, Dastych M Jr., Novotná H, Cíhalová J. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn’s disease. Dig Dis Sci. 2008;53(10):2789-2792.
102. Celli M, D’Eufemia P, Dommarco R, et al. Rapid gas-chromatographic assay of lactulose and mannitol for estimating intestinal permeability. Clin Chem. 1995;41(5):752-756.
103. Miki K, Butler R, Moore D, Davidson G. Rapid and simultaneous quantification of rhamnose, mannitol and lactulose in urine by HPLC for estimating intestinal permeability in pediatric practice. Clin Chem. 1996;42(1):71-75.
104. Lostia AM, Lionetto L, Principessa L, et al. A liquid chromatography/ mass spectrometry method for the evaluation of intestinal permeability. Clin Biochem. 2008;41(10-11):887-892.
105. van Nieuwenhoven MA, Geerling BJ, Deutz NE, Brouns F, Brummer RJ. The sensitivity of the lactulose/rhamnose gut permeability test. Eur J Clin Invest. 1999;29(2):160-165.
106. Di Leo V, Venturi C, Baragiotta A, et al. Gastroduodenal and intestinal permeability in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2003;15(9):967-973.
107. Hessels J, Snoeyink EJ, Platenkamp AJ, et al. Assessment of intestinal permeability: enzymatic determination of urinary mannitol, raffinose, sucrose and lactose on Hitachi analyzer. Clin Chem Lab Med. 2003;41(1):33-38.
108. Camilleri M, Nadeau A, Lamsam J, et al. Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion. Neurogastroenterol Motil. 2010;22(1): e15-e26.
109. Kubica P, Kot-Wasik A, Wasik A, Namieśnik J, Landowski P. Modern approach for determination of lactulose, mannitol and sucrose in human urine using HPLC-MS/MS for the studies of intestinal and upper digestive tract permeability. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;907:34-40.
110. Lee GO, Kosek P, Lima AA, et al. Lactulose: mannitol diagnostic test by HPLC and LC-MSMS platforms: considerations for field studies of intestinal barrier function and environmental enteropathy. J Pediatr Gastroenterol Nutr. 2014;59(4):544-550.
111. Murphy MS, Eastham EJ, Nelson R, Pearson AD, Laker MF. Intestinal permeability in Crohn’s disease. Arch Dis Child. 1989;64(3): 321-325.
112. Sutherland LR, Verhoef M, Wallace JL, et al. A simple, non invasive marker of gastric damage: sucrose permeability. Lancet. 1994;343: 998-1000.
113. Rabassa AA, Goodgame R, Sutton FM, Ou CN, Rognerud C, Graham DY. Effects of aspirin and Helicobacter pylori on the gastroduodenal mucosal permeability to sucrose. Gut. 1996;39(2):159-163
114. Kershavarzian A, Fields JZ, Vaeth J, et al. The differing effects of acute and chronic on gastric and intestinal permeability. Am J Gastroenterol. 1994;89:2205-2211.
115. Vogelsang H, Oberhuber G, Wyatt J. Lymphocytic gastritis and gastric permeability in patients with celiac disease. Gastroenterology. 1997;111:73-77.
116. Giofré MR, Meduri G, Pallio S, et al. Gastric permeability to sucrose is increased in portal hypertensive gastropathy. Eur J Gastroenterol Hepatol. 2000;12(5):529-533.
117. Senzolo M, Fries W, Buda A, et al. Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding? Am J Gastroenterol. 2009;104(12):3115-3116
118. Lv Y, Yang X, Zhao Y, et al. Separation and quantification of component monosaccharides of the tea polysaccharides from Gynostemma pentaphyllum by HPLC with indirect UV detection. Food Chem. 2009;112:742-746.
119. Cao Y, Wang Y, Chen X, et al. Study on sugar profile of rice during ageing by capillary electrophoresis with electrochemical detection. Food Chem. 2004;86:131-136.
120. Chavez-Servin JL, Castellote AI, Lopez-Sabater MC. Analysis of monoand disaccharides in milk-based formulae by high-performance liquid chromatography with refractive index detection. J Chromatogr A. 2004;1043(2):211-215.
121. Hutchinson JP, Remenyi T, Nesterenko P, et al. Investigation of polar organic solvents compatible with corona charged aerosol detection and their use for the determination of sugars by hydrophilic interaction liquid chromatography. Anal Chim Acta. 2012;750:199-206
122. Martínez-Augustin O, Boza JJ, Romera JM, Gil A. A rapid gas-liquid chromatography method for the determination of lactulose and mannitol in urine: clinical application in studies of intestinal permeability. Clin Biochem. 1995;28(4):401-405.
123. Ruiz-Matute AI, Hernández-Hernández O, Rodríguez-Sánchez S, Sanz ML, Martínez-Castro I. Derivatization of carbohydrates for GC and GC-MS analyses. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(17-18):1226-1240.
124. Pico J, Martínez MM, Martín MT, Gómez M. Quantification of sugars in wheat flours with an HPAEC-PAD method. Food Chem. 2015;173:674-681.
125. Gangola MP, Jaiswal S, Khedikar YP, Chibbar RN. A reliable and rapid method for soluble sugars and RFO analysis in chickpea using HPAEC-PAD and its comparison with HPLC-RI. Food Chem. 2014;154: 127-133.
126. You J, Sheng X, Ding C, et al. Detection of carbohydrates using new labeling reagent 1-(2-naphthyl)-3-methyl-5-pyrazolone by capillary zone electrophoresis with absorbance (UV). Anal Chim Acta. 2008;609(1):66-75.
127. Blanco Gomis D, Muro Tamayo D, Mangas Alonso JJ. Evolution of sugars in cider brandy aged in oak barrels: a contribution to its characterization. J Agric Food Chem. 2003;51(4):923-926
128. Medeiros PM, Simoneit BR. Analysis of sugars in environmental samples by gas chromatography-mass spectrometry. J Chromatogr A. 2007;1141(2):271-278.
129. Kakita H, Kamishima H, Komiya K, Kato Y. Simultaneous analysis of monosaccharides and oligosaccharides by high-performance liquid chromatography with postcolumn fluorescence derivatization. J Chromatogr A. 2002;961(1):77-82.
130. Račaitytė K, Kiessig S, Kálmán F. Application of capillary zone electrophoresis and reversed-phase high-performance liquid chromatography in the biopharmaceutical industry for the quantitative analysis of the monosaccharides released from a highly glycosylated therapeutic protein. J Chromatogr A. 2005;1079(1-2):354-365.
131. Marsilio R, D’Antiga L, Zancan L, Dussini N, Zacchello F. Simultaneous HPLC determination with light-scattering detection of lactulose and mannitol in studies of intestinal permeability in pediatrics. Clin Chem. 1998;44(8 pt 1):1685-1691.
132. Flick JA, Schnaar RL, Perman JA. Thin-layer chromatographic determination of urinary excretion of lactulose, simplified and applied to cystic fibrosis patients. Clin Chem. 1987;33(7):1211-1212
133. Vilela EG, Torres HO, Ferrari ML, Lima AS, Cunha AS. Gut permeability to lactulose and mannitol differs in treated Crohn’s disease and celiac disease patients and healthy subjects. Braz J Med Biol Res. 2008;41(12):1105-1109.
134. Sukkar SG, Schenone E, Foppiani L, Nobile MT. Experimental assessment of chemotherapy-induced early intestinal damage in colon cancer the lactulose-mannitol permeability test. Tumori. 2004; 90(5):461-463.
135. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. J Hepatol. 2014;61(3):642-659.
136. Vlachongiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol related decompensated cirrhosis. Aliment Pharmacol Ther. 2009; 29:992-999.
137. Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042.
138. Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol. 2011;17(24):2890-2896.
139. Liboredo JC, Ferrari Mde L, Vilela EG, et al. The effect of Saccharomyces boulardii in patients eligible for liver transplantation. Nutr Hosp. 2014;31:778-784.
140. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;(11):CD008716.
141. Zhang SC, Wang W, Ren WY, He BM, Zhou K, Zhu WN. Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis. World J Gastroenterol. 2003;9(3):534-538.
142. Sandhu BS, Gupta R, Sharma J, Singh J, Murthy NS, Sarin SK. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol. 2005;20(4):599-605.
143. Sommansson A, Saudi WS, Nylander O, Sjöblom M. Melatonin inhibits alcohol-induced increases in duodenal mucosal permeability in rats in vivo. Am J Physiol Gatsrointest Liver Physiol. 2013; 305(1):G95-G105.
144. Chen P, Torralba M, Tan J, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015;148(1): 203-214.
145. Úbeda M, Lario M, Muñoz L, et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol. 2016;64(5):1049-1057.
146. Verbeke L, Farre R, Verbinnen B, et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015;185(2):409-419.
147. Lippai D, Bala S, Catalano D, et al. MircoRNA-155 deficiency prevents alcohol induced serum endotoxin increase and small bowel inflammation in mice. Alcohol Clin Exp Res. 2014;38:2217-2224.